Beyond Air Inc (XAIR)
NASDAQ:XAIR
Want to see XAIR full AI Analyst Report?
XAIR Stock Chart & Stats
$0.54
-$0.04(-9.27%)
At close: 4:00 PM EST
$0.54
-$0.04(-9.27%)
Day’s Range― - ―
52-Week Range$0.43 - $5.84
Previous CloseN/A
Volume845.14K
Average Volume (3M)342.57K
Market Cap
$5.41M
Enterprise Value$14.53M
Total Cash (Recent Filing)$17.85M
Total Debt (Recent Filing)$24.82M
Price to Earnings (P/E)―
Beta0.04
Next Earnings
Jun 29, 2026EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding10,529,344
10 Day Avg. Volume627,403
30 Day Avg. Volume342,573
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.36
Price to Sales (P/S)4.98
P/FCF Ratio-0.42
Enterprise Value/Market Cap2.68
Enterprise Value/Revenue2.10
Enterprise Value/Gross Profit115.28
Enterprise Value/Ebitda-0.57
Forecast
1Y Price Target
$2.00Price Target Upside270.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.75
Revenue Forecast (FY)$12.75M
Bulls Say, Bears Say
Bulls Say
Clinical Adoption And KOL SupportPositive real-world feedback from healthcare professionals and incorporation of the LungFit PH system into key opinion leaders' clinical workflows indicate strong clinician acceptance and could reduce barriers to broader hospital adoption.
Commercial CompetitivenessAnalyst view that the LungFit PH system can be commercially competitive in the U.S. nitric oxide delivery market suggests potential to win meaningful market share as hospitals evaluate tankless delivery options.
Management ChangeAppointment of Robert Goodman as CEO brings an executive with a track record of ramping sales at medical technology companies, which could strengthen commercial strategy and execution for the LungFit PH system.
Bears Say
Asset Sale TerminationTermination of the agreement to sell NeuroNOS removes a previously anticipated source of cash and a strategic partnership, reducing expected non-dilutive funding and increasing financing uncertainty.
Demand Deferral RiskSome customers may postpone purchases of the current LungFit PH device while awaiting the next-generation model, which could depress near-term sales and slow the commercial ramp.
Regulatory And Commercialization DelayExpected timing delays for approval and commercialization of the second-generation system create uncertainty and are likely to limit near-term revenue momentum while execution risk remains elevated.
Beyond Air News
XAIR FAQ
What was Beyond Air Inc’s price range in the past 12 months?
Beyond Air Inc lowest stock price was $0.43 and its highest was $5.84 in the past 12 months.
What is Beyond Air Inc’s market cap?
Beyond Air Inc’s market cap is $5.41M.
When is Beyond Air Inc’s upcoming earnings report date?
Beyond Air Inc’s upcoming earnings report date is Jun 29, 2026 which is in 57 days.
How were Beyond Air Inc’s earnings last quarter?
Beyond Air Inc released its earnings results on Feb 13, 2026. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.75 by -$0.1.
Is Beyond Air Inc overvalued?
According to Wall Street analysts Beyond Air Inc’s price is currently Undervalued.
Does Beyond Air Inc pay dividends?
Beyond Air Inc does not currently pay dividends.
What is Beyond Air Inc’s EPS estimate?
Beyond Air Inc’s EPS estimate is -0.54.
How many shares outstanding does Beyond Air Inc have?
Beyond Air Inc has 10,529,344 shares outstanding.
What happened to Beyond Air Inc’s price movement after its last earnings report?
Beyond Air Inc reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.75. Following the earnings report the stock price went up 2.941%.
Which hedge fund is a major shareholder of Beyond Air Inc?
Currently, no hedge funds are holding shares in XAIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Beyond Air Inc
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
XAIR Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong operational momentum: double‑digit sequential growth, a 105% year‑over‑year revenue increase, a gross profit turnaround, significant cuts to operating costs (36% YoY) and extended commercial reach (45+ hospitals, VA sale, GPO coverage and 40-country distribution). Management secured additional capital and a pending NeuroNOS transaction that could de‑risk noncore R&D and create upside. Primary risks discussed were continued unprofitability and cash burn despite improvement, low absolute revenue and current gross margins, dependence on a contract manufacturer inspection and FDA timing for Gen II, lengthy sales cycles, and pending/contingent aspects of financing and the NeuroNOS sale. On balance the positive operational and financial momentum and progress toward Gen II and commercialization outweighed the remaining challenges.View all XAIR earnings summariesXAIR Stock 12 Month Forecast
Average Price Target
$2.00
▲(270.37% Upside)
Technical Analysis
Pulmonx
―
Hyperfine
―
TriSalus Life Sciences
―
Inspira Technologies Oxy BHN
―
Envoy Medical
―
Ownership Overview
86.18% Insiders
2.12% Mutual Funds
1.92% Other Institutional Investors
9.49% Public Companies and
Individual Investors